Eye institute and Dainippon to develop iPS cell-based therapies

04/1/2013 | Genetic Engineering & Biotechnology News

Retina Institute Japan will receive about $16 million in an investment from Dainippon Sumitomo Pharma as part of a deal to work on new induced pluripotent stem cell-based therapies. The investment will give Dainippon a 5% stake in the institute. The partnership's focus will include treatments for refractory retinal disease and age-related macular degeneration.

View Full Article in:

Genetic Engineering & Biotechnology News

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Senior Director, Biostatistics
Edwards Lifesciences
Irvine, CA
Diagnostic Technician
Roche
Marlborough, MA
Test Technician
Roche
Marlborough, MA
Associate - Food and Drug
Keller and Heckman LLP
Washington, DC
Senior Paralegal - Research & Development, and Medical
Boehringer Ingelheim
Ridgefield, CT